Article Abstract

Building a better mousetrap in the immunologic treatment of acute myeloid leukemia

Authors: John L. Reagan, Loren D. Fast


Sallman et al. report on the successful use of chimeric antigen receptor modified T cells (CAR-T cells) utilizing a Natural Killer Group 2D (NKG2D) target in a patient with acute myeloid leukemia (1).